Sanofi has made a $30 million strategic investment in MeiraGTx Holdings plc, a clinical stage gene therapy company, through the purchase of 4 million ordinary shares. Sanofi receives right of first negotiation to use MeiraGTx’s Riboswitch gene regulation technology for certain immunology, inflammation, and CNS targets, GLP-1 and other gut peptides for metabolic disease, and for MeiraGTx’s Phase 2 Xerostomia program. Riboswitch is a short sequence of DNA that can be added to a gene therapy ...